plasma rich fibrin

PreclinicalBiologic

KKing Abdullah University Hospital

plasma rich fibrin is one of 4 biologic programs targeting Platelet-rich Fibrin. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Platelet-Rich FibrinRecruiting

Platelet-Rich FibrinPreclinical

Recruiting

Competition

Competitive Landscape

3 competitors in Platelet-Rich Fibrin

#DrugCompanyPhaseTrials

Platelet Rich Fibrin

GGovernment Dental College and Research Institute, Bangalore

Preclinical

4 2

Platelet-Rich Fibrin (PRF)

FFederal University of São Paulo

Preclinical

2 3

Iprf

AAl-Azhar University

Preclinical

1 4

plasma rich fibrin

KKing Abdullah University Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ARecruiting

Platelet-Rich Fibrin

NCT06347640

Clinical

Trials by Indication[1]

Platelet-rich Fibrin1 trial

Outcome of Pulp Revascularization of Necrotic Mature Permanent Teeth Using Platelet-rich Fibrin

Recruiting·KKing Abdullah University Hospital·N/A·NCT06347640·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for plasma rich fibrin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — plasma rich fibrin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for plasma rich fibrin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — King Abdullah University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: KKing Abdullah University Hospital

plasma rich fibrin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Platelet-rich Fibrin1 trial

References

Drug Info

Quick Facts

Related News